Frederick Financial Consultants LLC Buys Shares of 1,000 United Therapeutics Co. (NASDAQ:UTHR)

Frederick Financial Consultants LLC purchased a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 1,000 shares of the biotechnology company's stock, valued at approximately $353,000.

Several other hedge funds have also recently bought and sold shares of UTHR. Commerce Bank increased its stake in United Therapeutics by 7.6% during the 4th quarter. Commerce Bank now owns 1,408 shares of the biotechnology company's stock worth $497,000 after acquiring an additional 100 shares during the period. Alpha DNA Investment Management LLC lifted its position in United Therapeutics by 7.8% during the fourth quarter. Alpha DNA Investment Management LLC now owns 2,255 shares of the biotechnology company's stock worth $796,000 after purchasing an additional 163 shares during the period. CANADA LIFE ASSURANCE Co grew its stake in United Therapeutics by 6.2% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 70,389 shares of the biotechnology company's stock worth $24,800,000 after buying an additional 4,110 shares in the last quarter. Farringdon Capital Ltd. acquired a new position in shares of United Therapeutics in the 4th quarter valued at approximately $292,000. Finally, NewEdge Advisors LLC lifted its holdings in shares of United Therapeutics by 124.6% during the 4th quarter. NewEdge Advisors LLC now owns 3,027 shares of the biotechnology company's stock worth $1,068,000 after acquiring an additional 1,679 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently weighed in on UTHR shares. UBS Group increased their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. HC Wainwright restated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. Finally, StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $388.25.

Insider Transactions at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $370.71, for a total value of $3,707,100.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $955,319.67. This represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, April 17th. The stock was sold at an average price of $283.78, for a total value of $3,121,580.00. Following the sale, the executive vice president now owns 36,781 shares in the company, valued at $10,437,712.18. This trade represents a 23.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 91,500 shares of company stock worth $30,971,540 in the last quarter. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Trading Down 0.2 %

NASDAQ UTHR traded down $0.46 during trading hours on Friday, hitting $284.73. The company's stock had a trading volume of 302,945 shares, compared to its average volume of 452,318. The company's 50-day simple moving average is $316.61 and its two-hundred day simple moving average is $348.62. The company has a market capitalization of $12.79 billion, a PE ratio of 12.50, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a 52 week low of $233.28 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the previous year, the firm earned $4.36 earnings per share. Research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.